Dees

The Inner Circle Acknowledges, Michael H. Schwartzberg as a Top Pinnacle Platinum Member for his contributions in the fields of Personal Injury Law and Music

Retrieved on: 
Thursday, September 7, 2023

BATON ROUGE, La., Sept. 7, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Michael H. Schwartzberg is acknowledged as a Top Pinnacle Platinum Member for his contributions in the fields of Personal Injury Law and Music.

Key Points: 
  • BATON ROUGE, La., Sept. 7, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Michael H. Schwartzberg is acknowledged as a Top Pinnacle Platinum Member for his contributions in the fields of Personal Injury Law and Music.
  • Mr. Schwartzberg pursued higher education at Louisiana State University where he earned a Bachelor's Degree in Music Education at Louisiana State University and a Master's Degree in Music at Boston University.
  • He then attended Louisiana State University and graduated with a Juris Doctorate from the  Paul M. Hebert Law Center at Louisiana State University.
  • Aside from his professional pursuits, Mr. Schwartzberg is a native of New Orleans, Louisiana and has resided in Lake Charles since 1986.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, February 7, 2023

BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the fourth quarter and full year 2022.

Key Points: 
  • The primary endpoint is change from baseline to day 56 in the modified Activities of Daily Living (mADL1) score.
  • Following topline results, Praxis intends to request an end-of-Phase 2 meeting with the FDA and initiate its ulixacaltamide Phase 3 development program for the treatment of ET in mid-2023.
  • Topline results from the Phase 1 study are expected in mid-2023, with plans to initiate a Phase 2 study in focal epilepsy in the fourth quarter of 2023.
  • In December 2022, Praxis presented the following posters at the American Epilepsy Society (AES) 2022 Annual Meeting:

Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Retrieved on: 
Monday, December 5, 2022

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers.
  • The primary objectives of this open-label, Phase 1 study are to assess the CNS PK and PD of orally administered LP352 in healthy adult male and female participants (n=10 in each Cohort).
  • At steady state, LP352 12 mg TID mean concentrations exceeded the Ki value for 5-HT2C activity throughout the dosing interval.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

Retrieved on: 
Friday, December 2, 2022

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.

Key Points: 
  • SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.
  • Data was collected from more than 17,000 patients through Invitae Corporation's Behind the Seizure Program, of which Neurocrine Biosciences is a sponsor.
  • These data (Poster #2.099: Demographic and Clinical Characteristics of Pediatric Patients with SCN8A-related Epilepsies: Results from a No-Charge Epilepsy Gene Panel) will be shared at the AES 2022 Annual Meeting in Nashville, Tennessee, December 26, 2022.
  • Data analysis demonstrated that 36 (0.2%) of the patients had an SCN8A variant that was classified as pathogenic (P) or likely pathogenic (LP).

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Retrieved on: 
Tuesday, November 29, 2022

We are committed to improving the lives of people living with rare epilepsies, and are pleased to have a meaningful presence at AES this year.

Key Points: 
  • We are committed to improving the lives of people living with rare epilepsies, and are pleased to have a meaningful presence at AES this year.
  • We look forward to presenting data highlighting the intrinsic characteristics of LP352, as well as hosting discussions around our ongoing PACIFIC study and future development plans.
  • Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs).
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Monday, November 28, 2022

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.

Key Points: 
  • BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
  • Although Praxis forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies

Retrieved on: 
Monday, November 28, 2022

The EMBOLD Study is expected to initiate in the U.S in the first quarter of 2023, with two distinct cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients.

Key Points: 
  • The EMBOLD Study is expected to initiate in the U.S in the first quarter of 2023, with two distinct cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients.
  • Approximately 20 participants will be enrolled in a total of 2 distinct cohorts (n10 for SCN2A-DEE and n10 for SCN8A-DEE).
  • PRAX-562 has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel blocking effects.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2022.
  • LP659, an oral, selective, centrally acting S1P receptor modulator, for which we have a pre-IND meeting scheduled with the FDA in the fourth quarter of 2022.
  • Third Quarter 2022 Financial Results:
    At September 30, 2022, Longboards cash, cash equivalents and short-term investments were approximately $77.3 million.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting

Retrieved on: 
Tuesday, October 11, 2022

Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs.

Key Points: 
  • Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs.
  • "Ambit's methodology underscores the need for more treatment options to improve outcomes and quality of life for the rare DEE population."
  • Ambit chief executive officer, Robert Sederman, will present this methodology on Oct. 13 as part of the Platform II Presentation Session (PL2-1) at the 2022 Annual Child Neurology Society Meeting.
  • Ambit Inc. is a data and technology-enabled biopharma and healthcare services company with a focus on rare and specialty disease.

Imperial Dade Adds Scale in Southeast, Acquires Dees Paper Company

Retrieved on: 
Monday, October 3, 2022

Imperial Dade, a leading distributor of foodservice packaging and janitorial supplies, today announced the acquisition of Dees Paper Company (Dees or the Company).

Key Points: 
  • Imperial Dade, a leading distributor of foodservice packaging and janitorial supplies, today announced the acquisition of Dees Paper Company (Dees or the Company).
  • The transaction represents the 54th acquisition for Imperial Dade under the leadership of Robert and Jason Tillis, Chairman and CEO of Imperial Dade, respectively.
  • "We are excited about the future of Dees under the leadership of Imperial Dade.
  • said Monty Dees, owner and CEO of Dees Paper Company.